Molecular targeted therapies in head and neck cancer - An update of recent developements - An u

Head and Neck Oncology

Volumn 2, Issue 1, 2010, Pages

  Goerner, Martin ^a   Seiwert, Tanguy Y ^b   Sudhoff, Holger ^a  

^a University Hospital of Bielefeld   (Germany)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DASATINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOCAL ADHESION KINASE; GEFITINIB; IRINOTECAN; LAPATINIB; MESSENGER RNA; METHOTREXATE; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (TETRAHYDRO 3 FURYLOXY) 6 QUINAZOLINYL] 4 DIMETHYLAMINO 2 BUTENAMIDE; PACLITAXEL; PANITUMUMAB; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; STAT PROTEIN; SUNITINIB; TRANSFORMING GROWTH FACTOR ALPHA; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; ZALUTUMUMAB; VASCULOTROPIN RECEPTOR;

ACNE; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FLUID RETENTION; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; HYPERTENSION; INJECTION SITE REACTION; LOW DRUG DOSE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR VASCULARIZATION; DRUG ANTAGONISM; HEAD AND NECK TUMOR; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY;

HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 77953392968     PISSN: None     EISSN: 17583284     Source Type: Journal    
DOI: 10.1186/1758-3284-2-8     Document Type: Review

References (30)

1. Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition. A Bozec F-X Gros F Penault-Llorca Formento Patricia Cayre Anne Dental Clélia Etienne-Grimaldi Marie-Christine Fischel Jean-Louis Milano Gérard, Eur J Cancer 2008 13 1922 1930 10.1016/j.ejca.2008.07.013
2. HPV & head and neck cancer: a descriptive update. PK Goon MA Stanley J Ebmeyer Steinsträsser Lars Upile Tahwinder Jerjes Waseem Bernal-Sprekelsen Manuel Görner Martin Sudhoff Holger H, Head Neck Oncol 2009 1 36 10.1186/1758-3284-1-36 19828033
3. Evolving treatment of advanced colon cancer. NH Segal LB Saltz, Annu Rev Med 2009 207 219 10.1146/annurev.med.60.041807.132435 19630571
4. Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells. M Iwase S Takaoka M Uchida Yoshiba Sayaka Kondo Gen Watanabe Hitoshi Ohashi Masaru Nagumo Masao, Oral Oncol 2008 4 361 368 10.1016/j.oraloncology.2007.04.006 (Pubitemid 351380981)
5. Epidermal growth factor receptor biology in head and neck cancer. S Kalyankrishna JR Grandis, J Clin Oncol 2006 17 2666 2672 10.1200/JCO.2005.04. 8306 (Pubitemid 46622088)
6. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. JR Grandis DJ Tweardy, Cancer Res 1993 15 3579 3584
7. Augmentation of radiation response with the vascular targeting agent ZD6126. T Hoang S Huang E Armstrong Eickhoff Jens C Harari Paul M, Int J Radiat Oncol Biol Phys 2006 5 1458 1465
8. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. SM Huang JM Bock PM Harari, Cancer Res 1999 8 1935 1940
9. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Mendelsohn J Baselga, J Clin Oncol 2003 14 2787 2799 10.1200/JCO.2003.01.504 (Pubitemid 46606324)
10. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. LJ Wirth AM Allen MR Posner RI Haddad Y Li JR Clark PM Busse AW Chan LA Goguen CM Norris DJ Annino RB Tishler, Ann Oncol 2009
11. FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer. RM Giusti MH Cohen P Keegan R Pazdur, Oncologist 2009 3 284 290 10.1634/theoncologist.2008-0254
12. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. WK Bleeker JJ van Lammerts Bueren HH van Ojik AF Gerritsen M Pluyter M Houtkamp E Halk J Goldstein J Schuurman MA van Dijk JGJ van de Winkel PW Parren, J Immunol 2004 7 4699 4707
13. Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. AM Egloff JR Grandis, Semin Oncol 2008 3 286 297 10.1053/j.seminoncol.2008.03.008 (Pubitemid 351787698)
14. Current situation of zalutumumab. F Rivera M Salcedo N Vega Y Blanco C Lápez, Expert Opin Biol Ther 2009 5 667 674 10.1517/14712590902932871
15. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. JA Bonner PM Harari J Giralt N Azarnia DM Shin RB Cohen CU Jones R Sur R Raben J Jassem R Ove MS Kies J Baselga H Youssoufian N Amellal EK Rowinsky K K Ang, N Engl J Med 2006 6 567 578 10.1056/NEJMoa053422 (Pubitemid 43209104)
16. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. JA Bonner PM Harari J Giralt RB Cohen CU Jones RK Sur D Raben J Baselga SA Spencer J Zhu H Youssoufian EK Rowinsky K K Ang, Lancet Oncol 2009 19897418
17. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. F Rivera A García-Castão N Vega E Maria Vega-Villegas L Gutiérrez-Sanz, Expert Rev Anticancer Ther 2009 10 1421 1428 10.1586/era.09.113
18. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. JB Vermorken RS Herbst X Leon N Amellal J Baselga, Cancer 2008 12 2710 2719 10.1002/cncr.23442 (Pubitemid 351969215)
19. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. X Leán R Hitt M Constenla A Rocca R Stupp AF Kovcs N Amellal EH Bessa J Bourhis, Clin Oncol (R Coll Radiol) 2005 6 418 424
20. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. JS Stewart EE Cohen L Licitra CM van Herpen C Khorprasert D Soulieres P Vodvarka D Rischin AM Garin FR Hirsch M Varella-Garcia S Ghiorghiu L Hargreaves A Armour A Speake A Swaisland EE Vokes, J Clin Oncol 2009 11 1864 1871 10.1200/JCO.2008.17.0530
21. Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR. B Hegymegi-Barakonyi D Eros C Szntai-Kis N Breza P Bnhegyi V Gbor Szabá E Vrkondi I Petk L Orfi G Kéri, Curr Opin Mol Ther 2009 3 308 321
22. Targeting angiogenesis in head and neck cancer. TY Seiwert EE Cohen, Semin Oncol 2008 3 274 285 10.1053/j.seminoncol.2008.03.005 (Pubitemid 351787696)
23. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. KJ Kim B Li J Winer M Armanini N Gillett HS Phillips N Ferrara, Nature 1993 6423 841 844 10.1038/362841a0 (Pubitemid 23132159)
24. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. EE Cohen DW Davis TG Karrison TY Seiwert SJ Wong S Nattam MF Kozloff JI Clark DH Yan W Liu C Pierce JE Dancey K Stenson E Blair A Dekker EE Vokes, Lancet Oncol 2009 3 247 257 10.1016/S1470-2045(09)70002-6
25. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. C Elser LL Siu E Winquist M Agulnik GR Pond SF Chin P Francis R Cheiken J Elting A McNabola D Wilkie O Petrenciuc EX Chen, J Clin Oncol 2007 24 3766 3773 10.1200/JCO.2006.10.2871 (Pubitemid 47372619)
26. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Q Zhang SM Thomas S Xi TE Smithgall JM Siegfried J Kamens WE Gooding R Jennifer Grandis, Cancer Res 2004 17 6166 6173 10.1158/0008-5472.CAN-04-0504 (Pubitemid 39129418)
27. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. DL Wheeler M Iida TJ Kruser MM Nechrebecki EF Dunn EA Armstrong S Huang PM Harari, Cancer Biol Ther 2009 8 696 703 19276677
28. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. FM Johnson B Saigal M Talpaz NJ Donato, Clin Cancer Res 2005 19 Pt 1 6924 6932 10.1158/1078-0432.CCR-05-0757 (Pubitemid 41428750)
29. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. CH Chung J Aulino NJ Muldowney H Hatakeyama J Baumann B Burkey J Netterville R Sinard WG Yarbrough AJ Cmelak RJ Slebos Y Shyr J Parker J Gilbert BA Murphy, Ann Oncol 2009 19850643
30. Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. AZ Dudek K Lesniewski-Kmak NJ Shehadeh ON Pandey M Franklin RA Kratzke EW Greeno P Kumar, Br J Cancer 2009 9 1379 1384 10.1038/sj.bjc.6605043